vs
AMPCO PITTSBURGH CORP（AP）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是AMPCO PITTSBURGH CORP的1.2倍（$127.1M vs $104.4M），再鼎医药同比增速更快（17.1% vs 11.5%），AMPCO PITTSBURGH CORP自由现金流更多（$-64.0K vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs -2.6%）
安普科匹兹堡公司是一家特种钢材制造商，总部位于宾夕法尼亚州匹兹堡市中心，1929年由多家此前已成立的小型钢铁企业合并组建而成。需要注意区分它和其他同样带有Ampco名称的企业，比如位于密尔沃基的铜基合金生产商、迈阿密的橱柜企业等。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
AP vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.2倍
$104.4M
营收增速更快
ZLAB
高出5.7%
11.5%
自由现金流更多
AP
多$26.6M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
-2.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $104.4M | $127.1M |
| 净利润 | $-57.7M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | -54.0% | -54.6% |
| 净利率 | -55.2% | — |
| 营收同比 | 11.5% | 17.1% |
| 净利润同比 | -1958.9% | — |
| 每股收益（稀释后） | $-2.87 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APZLAB
| Q4 25 | $104.4M | $127.1M | ||
| Q3 25 | $103.7M | $115.4M | ||
| Q2 25 | $108.9M | $109.1M | ||
| Q1 25 | $99.2M | $105.7M | ||
| Q4 24 | $93.6M | $108.5M | ||
| Q3 24 | $92.1M | $101.8M | ||
| Q2 24 | $107.1M | $100.1M | ||
| Q1 24 | $110.0M | $87.1M |
净利润APZLAB
| Q4 25 | $-57.7M | — | ||
| Q3 25 | $-2.2M | $-36.0M | ||
| Q2 25 | $-7.3M | $-40.7M | ||
| Q1 25 | $1.1M | $-48.4M | ||
| Q4 24 | $3.1M | — | ||
| Q3 24 | $-2.0M | $-41.7M | ||
| Q2 24 | $2.0M | $-80.3M | ||
| Q1 24 | $-2.7M | $-53.5M |
毛利率APZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率APZLAB
| Q4 25 | -54.0% | -54.6% | ||
| Q3 25 | 1.1% | -42.3% | ||
| Q2 25 | -2.8% | -50.3% | ||
| Q1 25 | 3.9% | -53.3% | ||
| Q4 24 | 5.5% | -62.6% | ||
| Q3 24 | 2.0% | -66.6% | ||
| Q2 24 | 4.7% | -76.0% | ||
| Q1 24 | 0.1% | -80.7% |
净利率APZLAB
| Q4 25 | -55.2% | — | ||
| Q3 25 | -2.1% | -31.2% | ||
| Q2 25 | -6.7% | -37.3% | ||
| Q1 25 | 1.2% | -45.8% | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | -2.1% | -40.9% | ||
| Q2 24 | 1.9% | -80.2% | ||
| Q1 24 | -2.5% | -61.4% |
每股收益（稀释后）APZLAB
| Q4 25 | $-2.87 | $-0.05 | ||
| Q3 25 | $-0.11 | $-0.03 | ||
| Q2 25 | $-0.36 | $-0.04 | ||
| Q1 25 | $0.06 | $-0.04 | ||
| Q4 24 | $0.16 | $-0.09 | ||
| Q3 24 | $-0.10 | $-0.04 | ||
| Q2 24 | $0.10 | $-0.08 | ||
| Q1 24 | $-0.14 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $10.7M | $689.6M |
| 总债务越低越好 | $117.9M | — |
| 股东权益账面价值 | $32.6M | $715.5M |
| 总资产 | $495.4M | $1.2B |
| 负债/权益比越低杠杆越低 | 3.61× | — |
8季度趋势，按日历期对齐
现金及短期投资APZLAB
| Q4 25 | $10.7M | $689.6M | ||
| Q3 25 | $15.0M | $717.2M | ||
| Q2 25 | $9.9M | $732.2M | ||
| Q1 25 | $7.1M | $757.3M | ||
| Q4 24 | $15.4M | $779.7M | ||
| Q3 24 | $11.8M | $616.1M | ||
| Q2 24 | $7.9M | $630.0M | ||
| Q1 24 | $10.8M | $650.8M |
总债务APZLAB
| Q4 25 | $117.9M | — | ||
| Q3 25 | $119.0M | — | ||
| Q2 25 | $115.9M | — | ||
| Q1 25 | $115.0M | — | ||
| Q4 24 | $116.4M | — | ||
| Q3 24 | $116.0M | — | ||
| Q2 24 | $119.4M | — | ||
| Q1 24 | $116.2M | — |
股东权益APZLAB
| Q4 25 | $32.6M | $715.5M | ||
| Q3 25 | $60.1M | $759.9M | ||
| Q2 25 | $62.7M | $791.7M | ||
| Q1 25 | $64.6M | $810.8M | ||
| Q4 24 | $58.9M | $840.9M | ||
| Q3 24 | $61.3M | $667.7M | ||
| Q2 24 | $58.0M | $704.2M | ||
| Q1 24 | $56.3M | $762.2M |
总资产APZLAB
| Q4 25 | $495.4M | $1.2B | ||
| Q3 25 | $524.4M | $1.2B | ||
| Q2 25 | $537.2M | $1.2B | ||
| Q1 25 | $536.2M | $1.2B | ||
| Q4 24 | $530.9M | $1.2B | ||
| Q3 24 | $547.4M | $985.3M | ||
| Q2 24 | $560.8M | $987.4M | ||
| Q1 24 | $565.8M | $988.4M |
负债/权益比APZLAB
| Q4 25 | 3.61× | — | ||
| Q3 25 | 1.98× | — | ||
| Q2 25 | 1.85× | — | ||
| Q1 25 | 1.78× | — | ||
| Q4 24 | 1.98× | — | ||
| Q3 24 | 1.89× | — | ||
| Q2 24 | 2.06× | — | ||
| Q1 24 | 2.06× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.7M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $-64.0K | $-26.7M |
| 自由现金流率自由现金流/营收 | -0.1% | -21.0% |
| 资本支出强度资本支出/营收 | 2.7% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-8.1M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流APZLAB
| Q4 25 | $2.7M | $-26.0M | ||
| Q3 25 | $6.3M | $-32.0M | ||
| Q2 25 | $-2.3M | $-31.0M | ||
| Q1 25 | $-5.3M | $-61.7M | ||
| Q4 24 | $7.5M | $-55.8M | ||
| Q3 24 | $11.4M | $-26.8M | ||
| Q2 24 | $-5.3M | $-42.2M | ||
| Q1 24 | $4.5M | $-90.1M |
自由现金流APZLAB
| Q4 25 | $-64.0K | $-26.7M | ||
| Q3 25 | $3.3M | $-35.0M | ||
| Q2 25 | $-3.8M | $-33.9M | ||
| Q1 25 | $-7.5M | $-63.2M | ||
| Q4 24 | $3.7M | $-58.4M | ||
| Q3 24 | $8.4M | $-28.2M | ||
| Q2 24 | $-8.0M | $-42.9M | ||
| Q1 24 | $1.7M | $-91.1M |
自由现金流率APZLAB
| Q4 25 | -0.1% | -21.0% | ||
| Q3 25 | 3.2% | -30.4% | ||
| Q2 25 | -3.5% | -31.1% | ||
| Q1 25 | -7.5% | -59.9% | ||
| Q4 24 | 4.0% | -53.8% | ||
| Q3 24 | 9.1% | -27.7% | ||
| Q2 24 | -7.5% | -42.9% | ||
| Q1 24 | 1.5% | -104.5% |
资本支出强度APZLAB
| Q4 25 | 2.7% | 0.5% | ||
| Q3 25 | 2.9% | 2.6% | ||
| Q2 25 | 1.3% | 2.6% | ||
| Q1 25 | 2.2% | 1.5% | ||
| Q4 24 | 4.0% | 2.4% | ||
| Q3 24 | 3.2% | 1.3% | ||
| Q2 24 | 2.5% | 0.7% | ||
| Q1 24 | 2.6% | 1.1% |
现金转化率APZLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -4.62× | — | ||
| Q4 24 | 2.40× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -2.64× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AP
| Forged And Cast Mill Rolls | $67.0M | 64% |
| Air Handling Systems | $14.3M | 14% |
| Heat Exchange Coils | $13.1M | 13% |
| Centrifugal Pumps | $10.3M | 10% |
| Forged Engineered Products | $4.0M | 4% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
